Johnson & Johnson $JNJ Shares Purchased by Achmea Investment Management B.V.

Achmea Investment Management B.V. increased its position in shares of Johnson & Johnson (NYSE:JNJ) by 21.7% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 400,291 shares of the company’s stock after purchasing an additional 71,471 shares during the period. Johnson & Johnson accounts for about 0.9% of Achmea Investment Management B.V.’s investment portfolio, making the stock its 15th largest holding. Achmea Investment Management B.V.’s holdings in Johnson & Johnson were worth $74,222,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. AustralianSuper Pty Ltd boosted its position in shares of Johnson & Johnson by 632.0% in the 3rd quarter. AustralianSuper Pty Ltd now owns 89,183 shares of the company’s stock valued at $16,536,000 after purchasing an additional 77,000 shares during the period. J.W. Cole Advisors Inc. raised its holdings in Johnson & Johnson by 2.2% during the 3rd quarter. J.W. Cole Advisors Inc. now owns 130,934 shares of the company’s stock worth $24,278,000 after buying an additional 2,769 shares during the period. Guinness Asset Management LTD lifted its stake in Johnson & Johnson by 0.4% during the third quarter. Guinness Asset Management LTD now owns 1,383,195 shares of the company’s stock valued at $251,216,000 after buying an additional 5,994 shares in the last quarter. Treasurer of the State of North Carolina boosted its holdings in shares of Johnson & Johnson by 8.3% in the second quarter. Treasurer of the State of North Carolina now owns 1,234,945 shares of the company’s stock worth $188,638,000 after buying an additional 94,957 shares during the period. Finally, National Pension Service boosted its holdings in shares of Johnson & Johnson by 3.2% in the third quarter. National Pension Service now owns 4,926,569 shares of the company’s stock worth $913,484,000 after buying an additional 151,707 shares during the period. 69.55% of the stock is owned by institutional investors.

Johnson & Johnson Price Performance

JNJ opened at $237.15 on Thursday. The stock has a fifty day moving average price of $233.95 and a 200 day moving average price of $207.76. The company has a current ratio of 1.03, a quick ratio of 0.77 and a debt-to-equity ratio of 0.48. Johnson & Johnson has a 1 year low of $141.50 and a 1 year high of $251.71. The stock has a market cap of $571.21 billion, a price-to-earnings ratio of 21.46, a PEG ratio of 2.35 and a beta of 0.34.

Johnson & Johnson (NYSE:JNJ) last issued its earnings results on Saturday, January 31st. The company reported $2.46 earnings per share for the quarter. Johnson & Johnson had a return on equity of 33.04% and a net margin of 28.46%.The company had revenue of $24.28 billion for the quarter. Analysts forecast that Johnson & Johnson will post 10.58 EPS for the current fiscal year.

Johnson & Johnson Announces Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Tuesday, March 10th. Investors of record on Tuesday, February 24th were issued a $1.30 dividend. The ex-dividend date was Tuesday, February 24th. This represents a $5.20 dividend on an annualized basis and a yield of 2.2%. Johnson & Johnson’s dividend payout ratio is currently 47.06%.

Johnson & Johnson News Summary

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: FDA approves ICOTYDE (icotrokinra), J&J’s once‑daily oral IL‑23R targeted peptide for moderate‑to‑severe plaque psoriasis — a first‑in‑class oral alternative to leading injectable IL‑23 therapies that could expand patient access and drive new prescription revenue. US FDA approves J&J’s oral psoriasis pill
• Positive Sentiment: HSBC raised its JNJ price target to $280 (from $265) and reiterated a Buy, citing healthcare strength and likely improved near‑term fundamentals — this adds analyst support and gives upside cushion relative to current levels. HSBC Sees Healthcare Strength, Lifts Johnson & Johnson (JNJ) Price Target
• Neutral Sentiment: Analyst commentary and comparisons (e.g., J&J vs Merck) highlight relative strengths/risks across pipelines and cash flows — useful context but not an immediate catalyst. J&J or Merck? Key Factors Investors Must Weigh Right Now
• Neutral Sentiment: Market watchlists and “stocks to watch” mentions raise visibility but don’t change fundamentals immediately. 4 stocks to watch on Wednesday: T, M, MU, JNJ
• Negative Sentiment: Shares recently pulled back (reports of a slide and lower intraday volume) indicating short‑term profit‑taking despite the positive drug news and analyst upgrade; that pressure likely explains the stock trading down today. Johnson & Johnson (JNJ) Stock Slides as Market Rises: Facts to Know Before You Trade

Analyst Upgrades and Downgrades

A number of equities research analysts have recently issued reports on JNJ shares. Scotiabank restated an “outperform” rating on shares of Johnson & Johnson in a report on Thursday, January 22nd. Argus lifted their price objective on shares of Johnson & Johnson from $210.00 to $240.00 in a research report on Friday, January 23rd. Barclays boosted their target price on shares of Johnson & Johnson from $197.00 to $217.00 and gave the company an “equal weight” rating in a research note on Tuesday, December 30th. Wolfe Research raised their target price on Johnson & Johnson from $225.00 to $240.00 and gave the stock an “outperform” rating in a research report on Monday, January 5th. Finally, TD Cowen lifted their price target on Johnson & Johnson from $222.00 to $250.00 and gave the company a “buy” rating in a report on Thursday, January 22nd. One research analyst has rated the stock with a Strong Buy rating, seventeen have given a Buy rating and nine have given a Hold rating to the company. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $236.17.

Insider Buying and Selling at Johnson & Johnson

In other Johnson & Johnson news, EVP Vanessa Broadhurst sold 6,197 shares of the firm’s stock in a transaction dated Tuesday, February 17th. The stock was sold at an average price of $243.39, for a total transaction of $1,508,287.83. Following the transaction, the executive vice president directly owned 23,003 shares in the company, valued at $5,598,700.17. This trade represents a 21.22% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Timothy Schmid sold 22,623 shares of the stock in a transaction dated Wednesday, February 18th. The shares were sold at an average price of $244.33, for a total value of $5,527,477.59. Following the transaction, the executive vice president directly owned 26,769 shares in the company, valued at approximately $6,540,469.77. This represents a 45.80% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 30,142 shares of company stock worth $7,360,528 over the last three months. Company insiders own 0.16% of the company’s stock.

Johnson & Johnson Company Profile

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company’s pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.